| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.RES.73.1.210 |
| P698 | PubMed publication ID | 8508531 |
| P50 | author | Bernard Fermini | Q67656054 |
| P2093 | author name string | Z Wang | |
| A M Brown | |||
| S Nattel | |||
| D Fedida | |||
| B Wible | |||
| F Faust | |||
| P433 | issue | 1 | |
| P304 | page(s) | 210-216 | |
| P577 | publication date | 1993-07-01 | |
| P1433 | published in | Circulation Research | Q2599020 |
| P1476 | title | Identity of a novel delayed rectifier current from human heart with a cloned K+ channel current | |
| P478 | volume | 73 |
| Q33567494 | 18β-Glycyrrhetinic acid preferentially blocks late Na current generated by ΔKPQ Nav1.5 channels. |
| Q40173326 | A high-Na(+) conduction state during recovery from inactivation in the K(+) channel Kv1.5. |
| Q36894709 | A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG. |
| Q37031587 | A multiple ion channel blocker, NIP-142, for the treatment of atrial fibrillation |
| Q37073576 | A pilot study to estimate the feasibility of assessing the relationships between polymorphisms in hKv1.5 and atrial fibrillation in patients following coronary artery bypass graft surgery |
| Q39476565 | Acacetin causes a frequency- and use-dependent blockade of hKv1.5 channels by binding to the S6 domain |
| Q34017931 | Activation and inactivation kinetics of an E-4031-sensitive current from single ferret atrial myocytes. |
| Q28484383 | Allitridi inhibits multiple cardiac potassium channels expressed in HEK 293 cells |
| Q41098028 | Allosteric effects of permeating cations on gating currents during K+ channel deactivation |
| Q61965157 | Alterations in potassium channel gene expression in atria of patients with persistent and paroxysmal atrial fibrillation: differential regulation of protein and mRNA levels for K+channels |
| Q40783466 | Altered state dependence of c-type inactivation in the long and short forms of human Kv1.5. |
| Q24297846 | Amino-terminal determinants of U-type inactivation of voltage-gated K+ channels |
| Q40086058 | An activation gating switch in Kv1.2 is localized to a threonine residue in the S2-S3 linker. |
| Q53943964 | Antiarrhythmic drugs and cardiac ion channels: mechanisms of action. |
| Q79366225 | Antiarrhythmic drugs: past, present, and future |
| Q38111636 | Atrial selectivity of antiarrhythmic drugs |
| Q26864362 | CaMKII regulation of cardiac K channels |
| Q47772758 | Cardiac potassium channels in health and disease |
| Q34118718 | Characterisation of the human voltage-gated potassium channel gene, KCNA7, a candidate gene for inherited cardiac disorders, and its exclusion as cause of progressive familial heart block I (PFHBI). |
| Q71806031 | Characterization of an ultrarapid delayed rectifier potassium channel involved in canine atrial repolarization |
| Q33508808 | Characterization of multiple ion channels in cultured human cardiac fibroblasts |
| Q37308410 | Cholesterol modulates the recruitment of Kv1.5 channels from Rab11-associated recycling endosome in native atrial myocytes |
| Q44796320 | Clarithromycin reduces Isus and Ito currents in human atrial myocytes with minor repercussions on action potential duration |
| Q46914960 | Comparison of potent Kv1.5 potassium channel inhibitors reveals the molecular basis for blocking kinetics and binding mode. |
| Q35106110 | Comparison of the effects of a transient outward potassium channel activator on currents recorded from atrial and ventricular cardiomyocytes |
| Q92938650 | Computational Study of the Loss-of-Function Mutations in the Kv1.5 Channel Associated with Atrial Fibrillation |
| Q39866309 | Control of voltage-gated K+ channel permeability to NMDG+ by a residue at the outer pore. |
| Q73020161 | Differences between outward currents of human atrial and subepicardial ventricular myocytes |
| Q48634800 | Downregulation of Kv1.5 K channels by the AMP-activated protein kinase |
| Q36303805 | Drug therapy for atrial fibrillation: where do we go from here? |
| Q38918724 | Dynamics and modulation studies of human voltage gated Kv1.5 channel |
| Q34180074 | Effect of external pH on activation of the Kv1.5 potassium channel |
| Q51759464 | Effects of dapoxetine on cloned Kv1.5 channels expressed in CHO cells. |
| Q43261549 | Effects of diltiazem and nifedipine on transient outward and ultra-rapid delayed rectifier potassium currents in human atrial myocytes |
| Q42928203 | Effects of lobeline, a nicotinic receptor ligand, on the cloned Kv1.5 |
| Q36193646 | Effects of n-3 Polyunsaturated Fatty Acids on Cardiac Ion Channels |
| Q33206302 | Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels. |
| Q44367464 | Effects of the chromanol HMR 1556 on potassium currents in atrial myocytes |
| Q46457364 | Electropharmacological properties of telmisartan in blocking hKv1.5 and HERG potassium channels expressed on Xenopus laevis oocytes |
| Q40330250 | Electrophysiological characterization of three non-synonymous single nucleotide polymorphisms (R87Q, A251T, and P307S) found in hKv1.5. |
| Q39956876 | External Ba2+ block of human Kv1.5 at neutral and acidic pH: evidence for Ho+-induced constriction of the outer pore mouth at rest. |
| Q28755230 | External K(+) relieves the block but not the gating shift caused by Zn(2+) in human Kv1.5 potassium channels |
| Q24318889 | Functional differences in Kv1.5 currents expressed in mammalian cell lines are due to the presence of endogenous Kv beta 2.1 subunits |
| Q41120655 | Gating charge and ionic currents associated with quinidine block of human Kv1.5 delayed rectifier channels |
| Q40195554 | Gating charge immobilization caused by the transition between inactivated states in the Kv1.5 channel |
| Q40970162 | Gating current studies reveal both intra- and extracellular cation modulation of K+ channel deactivation |
| Q24306905 | Genetic variation in KCNA5: impact on the atrial-specific potassium current IKur in patients with lone atrial fibrillation |
| Q48367671 | Genistein and tyrphostin AG556 decrease ultra-rapidly activating delayed rectifier K+ current of human atria by inhibiting EGF receptor tyrosine kinase. |
| Q40887315 | High affinity blockade of the HERG cardiac K(+) channel by the neuroleptic pimozide |
| Q42920113 | Human cardiac potassium channel DNA polymorphism modulates access to drug-binding site and causes drug resistance |
| Q41892767 | Identification of a pharmacological target for genioglossus reactivation throughout sleep |
| Q40969037 | Identification, cloning and expression of rabbit vascular smooth muscle Kv1.5 and comparison with native delayed rectifier K+ current |
| Q35129668 | Improved functional expression of human cardiac kv1.5 channels and trafficking-defective mutants by low temperature treatment |
| Q31940163 | Influence of permeating ions on Kv1.5 channel block by nifedipine |
| Q37230979 | Inhibitory actions of the phosphatidylinositol 3-kinase inhibitor LY294002 on the human Kv1.5 channel |
| Q43800920 | Inhibitory effect of bepridil on hKv1.5 channel current: comparison with amiodarone and E-4031. |
| Q51744933 | Interaction of DPP10a with Kv4.3 channel complex results in a sustained current component of human transient outward current Ito. |
| Q37833065 | Intravenous vernakalant: a review of its use in the management of recent-onset atrial fibrillation |
| Q47580184 | Ion Channel Trafficking: Control of Ion Channel Density as a Target for Arrhythmias? |
| Q40834298 | Is there a future for antiarrhythmic drug therapy? |
| Q33960965 | K(+) channels as therapeutic drug targets |
| Q37406359 | K+ current changes account for the rate dependence of the action potential in the human atrial myocyte |
| Q39687841 | Kinetic analysis of the effects of H+ or Ni2+ on Kv1.5 current shows that both ions enhance slow inactivation and induce resting inactivation. |
| Q48007771 | Kv1.5 blockers preferentially inhibit TASK-1 channels: TASK-1 as a target against atrial fibrillation and obstructive sleep apnea? |
| Q42633034 | Ligand binding to the voltage-gated Kv1.5 potassium channel in the open state--docking and computer simulations of a homology model |
| Q24318903 | Localization of the Kv1.5 K+ channel protein in explanted cardiac tissue |
| Q39568164 | Mathematical simulations of ligand-gated and cell-type specific effects on the action potential of human atrium. |
| Q89982580 | Mechanical stretch increases Kv1.5 current through an interaction between the S1-S2 linker and N-terminus of the channel |
| Q41219769 | Mechanisms of block of a human cloned potassium channel by the enantiomers of a new bradycardic agent: S-16257-2 and S-16260-2. |
| Q42513131 | Membrane cholesterol modulates Kv1.5 potassium channel distribution and function in rat cardiomyocytes |
| Q74525925 | Modulation of slow inactivation in human cardiac Kv1.5 channels by extra- and intracellular permeant cations |
| Q38116835 | Modulation of voltage-gated ion channels by sialylation |
| Q44631900 | Molecular basis for Kv1.5 channel block: conservation of drug binding sites among voltage-gated K+ channels |
| Q33931559 | Molecular basis of functional voltage-gated K+ channel diversity in the mammalian myocardium |
| Q31817227 | Molecular biology of K(+) channels and their role in cardiac arrhythmias |
| Q40666420 | Molecular biology of voltage-gated K+ channels in heart |
| Q24317128 | Molecular cloning and functional expression of a novel potassium channel beta-subunit from human atrium |
| Q77760405 | Molecular correlates of the calcium-independent, depolarization-activated K+ currents in rat atrial myocytes |
| Q43149418 | Molecular determinants of Kv1.5 channel block by diphenyl phosphine oxide-1. |
| Q36435699 | Molecular identification of SqKv1A. A candidate for the delayed rectifier K channel in squid giant axon |
| Q42455737 | Neurogenic contraction induced by the antiarrhythmic compound, AVE 0118, in rat small mesenteric arteries |
| Q40962992 | Non-specific action of methoxamine on Ito, and the cloned channels hKv 1.5 and Kv 4.2. |
| Q41047763 | On the mechanism by which 4-Aminopyridine occludes quinidine block of the cardiac K+ channel, hKv1.5. |
| Q37766393 | Optimizing the management of atrial fibrillation: focus on current guidelines and the impact of new agents on future recommendations |
| Q43105838 | PKC inhibition results in a Kv 1.5 + Kv β1.3 pharmacology closer to Kv 1.5 channels. |
| Q43710067 | Pergolide block of the cloned Kv1.5 potassium channels |
| Q35645901 | Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing |
| Q85174031 | Pharmacology of Cardiac Potassium Channels |
| Q38042919 | Polyunsaturated Fatty acids modify the gating of kv channels |
| Q38235209 | Potassium channels in pancreatic duct epithelial cells: their role, function and pathophysiological relevance |
| Q43920140 | Potassium currents in the heart: functional roles in repolarization, arrhythmia and therapeutics |
| Q42913495 | Presence and functional role of the rapidly activating delayed rectifier K+ current in left and right atria of adult mice |
| Q46383938 | Presence of the Kv1.5 K(+) channel in the sinoatrial node |
| Q38819288 | Promoter Methylation Analysis Reveals That KCNA5 Ion Channel Silencing Supports Ewing Sarcoma Cell Proliferation |
| Q42202086 | Protein kinase C (PKC) activity regulates functional effects of Kvβ1.3 subunit on KV1.5 channels: identification of a cardiac Kv1.5 channelosome |
| Q38972404 | Putative binding sites for arachidonic acid on the human cardiac Kv 1.5 channel |
| Q46262984 | Quercetin activates human Kv1.5 channels by a residue I502 in the S6 segment |
| Q51354497 | Regulation of human cardiac Kv1.5 channels by extracellular acidification. |
| Q40893674 | Regulation of transient Na+ conductance by intra- and extracellular K+ in the human delayed rectifier K+ channel Kv1.5. |
| Q31997375 | Regulation of voltage-gated K+ channel expression in the developing mammalian myocardium |
| Q37282970 | Remodelling of cardiac repolarization: how homeostatic responses can lead to arrhythmogenesis. |
| Q42694191 | Revealing kinetics and state-dependent binding properties of IKur-targeting drugs that maximize atrial fibrillation selectivity. |
| Q40397556 | Separation of P/C- and U-type inactivation pathways in Kv1.5 potassium channels |
| Q40343935 | Single channel analysis reveals different modes of Kv1.5 gating behavior regulated by changes of external pH. |
| Q41184284 | Slow gating charge immobilization in the human potassium channel Kv1.5 and its prevention by 4-aminopyridine |
| Q37594973 | Specificities of atrial electrophysiology: Clues to a better understanding of cardiac function and the mechanisms of arrhythmias |
| Q36874778 | Stable expression and characterization of the human brain potassium channel Kv2.1: blockade by antipsychotic agents |
| Q34046966 | Stereoselective block of a human cardiac potassium channel (Kv1.5) by bupivacaine enantiomers |
| Q28346372 | Stereoselective effects of the enantiomers of a new local anaesthetic, IQB-9302, on a human cardiac potassium channel (Kv1.5) |
| Q58860331 | Strategies for atrial fibrillation therapy: focusing onIKurpotassium channel |
| Q37005224 | TASK-1 channels may modulate action potential duration of human atrial cardiomyocytes |
| Q28546551 | The Inhibitory Effects of Ca2+ Channel Blocker Nifedipine on Rat Kv2.1 Potassium Channels |
| Q57022048 | The N terminus and transmembrane segment S1 of Kv1.5 can coassemble with the rest of the channel independently of the S1-S2 linkage |
| Q42524309 | The anchoring protein SAP97 retains Kv1.5 channels in the plasma membrane of cardiac myocytes |
| Q35026648 | The antiarrhythmic agent bertosamil induces inactivation of the sustained outward K+ current in human atrial myocytes. |
| Q40277956 | The external K+ concentration and mutations in the outer pore mouth affect the inhibition of kv1.5 current by Ni2+. |
| Q41849017 | The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes |
| Q42673854 | The mechanism of atrial antiarrhythmic action of RSD1235. |
| Q40395459 | The treatment of atrial fibrillation. An evaluation of drug therapy, electrical modalities and therapeutic considerations. |
| Q48070587 | The voltage-dependent K+ channel (Kv1.5) cloned from rabbit heart and facilitation of inactivation of the delayed rectifier current by the rat beta subunit |
| Q37968125 | The voltage-gated channel accessory protein KCNE2: multiple ion channel partners, multiple ways to long QT syndrome |
| Q37821136 | Ultra-rapid delayed rectifier channels: molecular basis and therapeutic implications |
| Q98771654 | Ultrarapid Delayed Rectifier K+ Channelopathies in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes |
| Q40714348 | Uncoupling of gating charge movement and closure of the ion pore during recovery from inactivation in the Kv1.5 channel |
| Q36764028 | Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent |
| Q37107714 | Vernakalant in the management of atrial fibrillation |
| Q37769027 | Vernakalant: A novel agent for the termination of atrial fibrillation |
| Q37464784 | Voltage-gated potassium channels as therapeutic targets |
| Q22254099 | alpha-actinin-2 couples to cardiac Kv1.5 channels, regulating current density and channel localization in HEK cells |
| Q59248666 | Électrophysiologie de la fibrillation atriale |
Search more.